Will ARX's FY2026 investment gains comprise less than 10% of Adjusted EBITDA?
Current Prediction
Why This Question Matters
EBITDA quality is the core accounting integrity question. Q3 2025's 37% contribution from investment gains made underlying profitability nearly impossible to assess. If FY2026 EBITDA is generated primarily from operations, it validates the business model's earnings power. If gains persist at elevated levels, it confirms the Fugazi Filter's QUESTIONABLE classification.
Prediction Distribution
Individual Predictions(9 runs)
FY2026 guidance of $269M EBITDA is described explicitly as ex-investment gains. Management has set the expectation that gains will not be a material component. With $269M target, 10% threshold means gains need to stay below $27M. The Q3 2025 $39M gain was described as atypical.
Management explicit exclusion of gains from FY2026 guidance creates a strong anchor. The 10% threshold on $269M equals $27M in gains. For FY2026, gains above $27M would require another MGA sale or significant revaluations.
The strongest signal is management intent. Setting guidance ex-investment gains and then booking material gains would undermine credibility in early public reporting. MGA minority stake sales are discretionary management decisions. The $30M MGA sale was specific and non-repeating.
Management guidance explicitly excludes gains, creating a strong prior for YES. Given the incentive to establish credibility in year 2 as a public company, probability favors gains below 10%.
The similar-investments comment introduces uncertainty. Accelerant owns minority stakes in multiple MGAs. Mark-to-market revaluations or partner exits could generate gains involuntarily.
Resolution hinges on definitions. If investment gains narrowly means MGA sales and ecosystem revaluations, management can control this by not selling. The Q3 components were discretionary and unusual.
Management guided explicitly ex-gains. In year 2 post-IPO, credibility matters. The Q3 2025 gains were from a specific sale that will not repeat.
Favors YES but MGA ecosystem stakes create a reservoir of potential gains. Mark-to-market could trigger involuntary gains. Modest edge toward clean EBITDA year.
Management intent is the dominant signal. Guiding ex-gains and then reporting material gains would damage credibility. 60% probability for clean year.
Resolution Criteria
Resolves YES if ARX's FY2026 annual results show investment gains (MGA stake sales, ecosystem investment revaluations) constitute less than 10% of total Adjusted EBITDA. Resolves NO if investment gains are 10% or more of Adjusted EBITDA.
Resolution Source
ARX FY2026 10-K filing or FY2026 earnings call EBITDA bridge disclosure
Source Trigger
Monitor the proportion of Adjusted EBITDA derived from investment gains vs. underlying operations. Q3 2025 was 37% gains; this should normalize to near-zero.
Full multi-lens equity analysis